NLRP6 in infection and inflammation

Microbes and Infection

Volumn 15, Issue 10-11, 2013, Pages 661-668

  Anand, Paras K ^a   Kanneganti, Thirumala Devi ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Infection; Innate immunity; Intestinal homeostasis; Microbiota; NLR; NLRP6

Indexed keywords

BETA DEFENSIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN NLRP6; RANTES; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLITIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; INFECTION; INFLAMMATION; INTESTINE FLORA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

INFECTION; INNATE IMMUNITY; INTESTINAL HOMEOSTASIS; MICROBIOTA; NLR; NLRP6;

HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MICROBIOTA; NF-KAPPA B;

EID: 84884126316     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.06.009     Document Type: Short Survey

References (67)

1. Creagh E.M., O'Neill L.A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006, 27:352-357.
2. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009, 21:317-337.
3. Anand P.K., Tait S.W., Lamkanfi M., Amer A.O., Nunez G., Green D.R., Kanneganti T.D. TLR2 and RIP2 pathways mediate autophagy of Listeria monocytogenes via ERK activation. J. Biol. Chem. 2011, 286:42981-42991.
4. Franchi L., Kamada N., Nakamura Y., Burberry A., Kuffa P., Suzuki S., Shaw M.H., Kim Y.G., Nunez G. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 2012, 13:449-456.
5. Franchi L., Munoz-Planillo R., Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 2012, 13:325-332.
6. Kanneganti T.D. Central roles of NLRs and inflammasomes in viral infection. Nat. Rev. Immunol. 2010, 10:688-698.
7. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat. Immunol. 2012, 13:333-342.
8. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 2002, 10:417-426.
9. Kanneganti T.D., Lamkanfi M., Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007, 27:549-559.
10. Kanneganti T.D., Ozoren N., Body-Malapel M., Amer A., Park J.H., Franchi L., Whitfield J., Barchet W., Colonna M., Vandenabeele P., Bertin J., Coyle A., Grant E.P., Akira S., Nunez G. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440:233-236.
11. Anand P.K., Malireddi R.K., Kanneganti T.D. Role of the nlrp3 inflammasome in microbial infection. Front. Microbiol. 2011, 2:12.
12. Lupfer C., Thomas P.G., Anand P.K., Vogel P., Milasta S., Martinez J., Huang G., Green M., Kundu M., Chi H., Xavier R.J., Green D.R., Lamkanfi M., Dinarello C.A., Doherty P.C., Kanneganti T.D. Receptor interacting protein kinase 2-mediated mitophagy regulates inflammasome activation during virus infection. Nat. Immunol. 2013, 14:480-488.
13. Kofoed E.M., Vance R.E. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011, 477:592-595.
14. Zhao Y., Yang J., Shi J., Gong Y.N., Lu Q., Xu H., Liu L., Shao F. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011, 477:596-600.
15. Meissner T.B., Li A., Biswas A., Lee K.H., Liu Y.J., Bayir E., Iliopoulos D., van den Elsen P.J., Kobayashi K.S. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13794-13799.
16. Joly S., Eisenbarth S.C., Olivier A.K., Williams A., Kaplan D.H., Cassel S.L., Flavell R.A., Sutterwala F.S. Cutting edge: Nlrp10 is essential for protective antifungal adaptive immunity against Candida albicans. J. Immunol. 2012, 189:4713-4717.
17. Eisenbarth S.C., Williams A., Colegio O.R., Meng H., Strowig T., Rongvaux A., Henao-Mejia J., Thaiss C.A., Joly S., Gonzalez D.G., Xu L., Zenewicz L.A., Haberman A.M., Elinav E., Kleinstein S.H., Sutterwala F.S., Flavell R.A. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 2012, 484:510-513.
18. Khare S., Dorfleutner A., Bryan N.B., Yun C., Radian A.D., de Almeida L., Rojanasakul Y., Stehlik C. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 2012, 36:464-476.
19. Lei Y., Wen H., Yu Y., Taxman D.J., Zhang L., Widman D.G., Swanson K.V., Wen K.W., Damania B., Moore C.B., Giguere P.M., Siderovski D.P., Hiscott J., Razani B., Semenkovich C.F., Chen X., Ting J.P. The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity 2012, 36:933-946.
20. Schneider M., Zimmermann A.G., Roberts R.A., Zhang L., Swanson K.V., Wen H., Davis B.K., Allen I.C., Holl E.K., Ye Z., Rahman A.H., Conti B.J., Eitas T.K., Koller B.H., Ting J.P. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat. Immunol. 2012, 13:823-831.
21. Zaki M.H., Vogel P., Malireddi R.K., Body-Malapel M., Anand P.K., Bertin J., Green D.R., Lamkanfi M., Kanneganti T.D. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011, 20:649-660.
22. Allen I.C., Wilson J.E., Schneider M., Lich J.D., Roberts R.A., Arthur J.C., Woodford R.M., Davis B.K., Uronis J.M., Herfarth H.H., Jobin C., Rogers A.B., Ting J.P. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity 2012, 36:742-754.
23. Anand P.K., Malireddi R.K., Lukens J.R., Vogel P., Bertin J., Lamkanfi M., Kanneganti T.D. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature 2012, 488:389-393.
24. Centers for Disease Control and Prevention Inflammatory Bowel Disease (IBD) 2013, http://www.cdc.gov/ibd/.
25. Elinav E., Strowig T., Kau A., Henao-Mejia J., Thaiss C., Booth C., Peaper D., Bertin J., Eisenbarth S., Gordon J., Flavell R. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
26. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W., Strowig T., Thaiss C., Kau A., Eisenbarth S., Jurczak M., Camporez J.-P., Shulman G., Gordon J., Hoffman H., Flavell R. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
27. Centers for Disease Control and Prevention Colorectal (Colon) Cancer 2013, http://www.cdc.gov/cancer/colorectal/.
28. Chen G., Liu M., Wang F., Bertin J., Nunez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 2011, 186:7187-7194.
29. Normand S., Delanoye-Crespin A., Bressenot A., Huot L., Grandjean T., Peyrin-Biroulet L., Lemoine Y., Hot D., Chamaillard M. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9601-9606.
30. Ahmed F.E., Vos P. Molecular markers for human colon cancer in stool and blood identified by RT-PCR. Anticancer Res. 2004, 24:4127-4134.
31. Allen I.C., TeKippe E.M., Woodford R.M., Uronis J.M., Holl E.K., Rogers A.B., Herfarth H.H., Jobin C., Ting J.P. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 2010, 207:1045-1056.
32. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K.S., McIntire C.R., LeBlanc P.M., Meunier C., Turbide C., Gros P., Beauchemin N., Vallance B.A., Saleh M. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32:367-378.
33. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
34. Hirota S.A., Ng J., Lueng A., Khajah M., Parhar K., Li Y., Lam V., Potentier M.S., Ng K., Bawa M., McCafferty D.M., Rioux K.P., Ghosh S., Xavier R.J., Colgan S.P., Tschopp J., Muruve D., MacDonald J.A., Beck P.L. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 2011, 17:1359-1372.
35. Couturier-Maillard A., Secher T., Rehman A., Normand S., De Arcangelis A., Haesler R., Huot L., Grandjean T., Bressenot A., Delanoye-Crespin A., Gaillot O., Schreiber S., Lemoine Y., Ryffel B., Hot D., Nunez G., Chen G., Rosenstiel P., Chamaillard M. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 2013, 123:700-711.
36. Huber S., Gagliani N., Zenewicz L., Huber F., Bosurgi L., Hu B., Hedl M., Zhang W., O'Connor W., Murphy A., Valenzuela D., Yancopoulos G., Booth C., Cho J., Ouyang W., Abraham C., Flavell R. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
37. Villanueva T. Tumorigenesis: wound-up tumours. Nat. Rev. Cancer 2011, 11:235.
38. Yang W.S., Stockwell B.R. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol. 2008, 9:R92.
39. Sonnenberg G.F., Fouser L.A., Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 2011, 12:383-390.
40. Zaki M.H., Vogel P., Body-Malapel M., Lamkanfi M., Kanneganti T.D. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J. Immunol. 2010, 185:4912-4920.
41. Salcedo R., Worschech A., Cardone M., Jones Y., Gyulai Z., Dai R.M., Wang E., Ma W., Haines D., O'HUigin C., Marincola F.M., Trinchieri G. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 2010, 207:1625-1636.
42. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114. e2105.
43. Centers for Disease Control and Prevention 2010, http://www.cdc.gov/foodborneburden/2011-foodborne-estimates.html.
44. Anand P.K., Kanneganti T.D. Targeting NLRP6 to enhance immunity against bacterial infections. Future Microbiol. 2012, 7:1239-1242.
45. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21:11-19.
46. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
47. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008, 118:560-570.
48. Makino Y., Cook D.N., Smithies O., Hwang O.Y., Neilson E.G., Turka L.A., Sato H., Wells A.D., Danoff T.M. Impaired T cell function in RANTES-deficient mice. Clin. Immunol. 2002, 102:302-309.
49. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
50. Ajuebor M.N., Hogaboam C.M., Kunkel S.L., Proudfoot A.E., Wallace J.L. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J. Immunol. 2001, 166:552-558.
51. Andres P.G., Beck P.L., Mizoguchi E., Mizoguchi A., Bhan A.K., Dawson T., Kuziel W.A., Maeda N., MacDermott R.P., Podolsky D.K., Reinecker H.C. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodiumsulfate-mediated colitis: lack of CC chemokine receptor 5expression results in a NK1.1+ lymphocyte-associated Th2-typeimmune response in the intestine. J. Immunol. 2000, 164:6303-6312.
52. Crawford A., Angelosanto J.M., Nadwodny K.L., Blackburn S.D., Wherry E.J. A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection. PLoS Pathog. 2011, 7. e1002098.
53. Billstrom Schroeder M., Worthen G.S. Viral regulation of RANTES expression during human cytomegalovirus infection of endothelial cells. J. Virol. 2001, 75:3383-3390.
54. Sakthivel S.K., Singh U.P., Singh S., Taub D.D., Igietseme J.U., Lillard J.W. CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 2008, 8:136.
55. Santiago H.C., Oliveira C.F., Santiago L., Ferraz F.O., de Souza D.G., de-Freitas L.A., Afonso L.C., Teixeira M.M., Gazzinelli R.T., Vieira L.Q. Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major. Infect Immun. 2004, 72:4918-4923.
56. Werts C., le Bourhis L., Liu J., Magalhaes J.G., Carneiro L.A., Fritz J.H., Stockinger S., Balloy V., Chignard M., Decker T., Philpott D.J., Ma X., Girardin S.E. Nod1 and Nod2 induce CCL5/RANTES through the NF-kappaB pathway. Eur. J. Immunol. 2007, 37:2499-2508.
57. Corr S.C., O'Neill L.A. Listeria monocytogenes infection in the face of innate immunity. Cell. Microbiol. 2009, 11:703-709.
58. Grenier J.M., Wang L., Manji G.A., Huang W.J., Al-Garawi A., Kelly R., Carlson A., Merriam S., Lora J.M., Briskin M., DiStefano P.S., Bertin J. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett. 2002, 530:73-78.
59. Meixenberger K., Pache F., Eitel J., Schmeck B., Hippenstiel S., Slevogt H., N'Guessan P., Witzenrath M., Netea M.G., Chakraborty T., Suttorp N., Opitz B. Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3. J. Immunol. 2010, 184:922-930.
60. Kempster S.L., Belteki G., Forhead A.J., Fowden A.L., Catalano R.D., Lam B.Y., McFarlane I., Charnock-Jones D.S., Smith G.C. Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G253-G263.
61. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., Wu G.D. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 1999, 104:383-389.
62. Kaul D., Anand P.K., Khanna A. Functional genomics of PPAR-gamma in human immunomodulatory cells. Mol. Cell. Biochem. 2006, 290:211-215.
63. Sun Y., Zhang M., Chen C.C., Gillilland M., Sun X., El-Zaatari M., Huffnagle G.B., Young V.B., Zhang J., Hong S.C., Chang Y.M., Gumucio D.L., Owyang C., Kao J.Y. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013, 144:1478-1487. e1478.
64. Dubuquoy L., Rousseaux C., Thuru X., Peyrin-Biroulet L., Romano O., Chavatte P., Chamaillard M., Desreumaux P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006, 55:1341-1349.
65. Abdullah Z., Geiger S., Nino-Castro A., Bottcher J.P., Muraliv E., Gaidt M., Schildberg F.A., Riethausen K., Flossdorf J., Krebs W., Chakraborty T., Kurts C., Schultze J.L., Knolle P.A., Klotz L. Lack of PPARgamma in myeloid cells confers resistance to Listeria monocytogenes infection. PLoS One 2012, 7. e37349.
66. Mahajan S., Dkhar H.K., Chandra V., Dave S., Nanduri R., Janmeja A.K., Agrewala J.N., Gupta P. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARgamma and TR4 for survival. J. Immunol. 2012, 188:5593-5603.
67. Chen G.Y., Nunez G. Inflammasomes in intestinal inflammation and cancer. Gastroenterology 2011, 141:1986-1999.